The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Alzheimer Disease
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
-
Local Institution - 1217, Phoenix, Arizona, United States, 85006-2528
Local Institution - 1220, Scottsdale, Arizona, United States, 85260-6742
Local Institution - 1104, Anaheim, California, United States, 92805-5854
ATP Clinical Research, Costa Mesa, California, United States, 92626-4607
Local Institution - 1219, Los Angeles, California, United States, 90095
Local Institution - 1213, Rancho Cucamonga, California, United States, 91730
Local Institution - 1222, Farmington, Connecticut, United States, 06030
JY Research Institute Inc, Cutler Bay, Florida, United States, 33189-1232
Local Institution - 1023, Daytona Beach, Florida, United States, 32117-5531
Integrity Clinical Research, Llc, Doral, Florida, United States, 33122-1620
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
55 Years to 90 Years
ALL
No
Karuna Therapeutics,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2026-11-06